hVIVO (LON:HVO) Issues Earnings Results

hVIVO (LON:HVO) posted its quarterly earnings data on Tuesday. The company reported GBX (0.82) earnings per share (EPS) for the quarter, Digital Look Earnings reports. hVIVO had a negative net margin of 12.48% and a negative return on equity of 14.65%.

hVIVO Trading Down 4.7%

LON:HVO traded down GBX 0.30 during midday trading on Tuesday, hitting GBX 6.10. 4,701,018 shares of the company traded hands, compared to its average volume of 2,553,296. The firm has a market capitalization of £41.99 million, a P/E ratio of -7.01 and a beta of 1.69. The firm’s fifty day moving average is GBX 6.83 and its 200-day moving average is GBX 7.42. hVIVO has a 12-month low of GBX 4.30 and a 12-month high of GBX 11. The company has a current ratio of 1.63, a quick ratio of 1.16 and a debt-to-equity ratio of 38.75.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.